Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin

Received for publication, August 1, 2019, and in revised form, October 15, 2019 Published, Papers in Press, October 25, 2019, DOI 10.1074/jbc.A119.101034

© 2019 Wang et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

Yuetong Wang§, Jian Cao†, Weimei Liu†, Jiali Zhang‡, Zuo Wang‡, Yiqun Zhang‡, Linjun Hou‡, Shengmiao Chen§, Piliang Hao‡, Liye Zhang‡, Min Zhuang‡, Yang Yu‡, Dake Li¶, and Gaofeng Fan∥

From the §School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China, the ¶Department of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing 210004, China, the ∥Institute of Biophysics, Key Laboratory of RNA Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Beijing 100101, China

Edited by Eric R. Fearon

Despite a lack of mutations, accumulating evidence supports an important role for the Wnt/β-catenin pathway in ovarian tumorigenesis. However, the molecular mechanism that contributes to the aberrant activation of the Wnt signaling cascade in ovarian cancer has not been fully elucidated. Here, we found that protein tyrosine phosphatase receptor type R (PTPRR) suppressed the activation of the Wnt/β-catenin pathway in ovarian cancer. We performed an shRNA-based biochemical screen, which identified PTPRR as being responsible for tyrosine dephosphorylation of β-catenin on Tyr-142, a key site controlling the transcriptional activity of β-catenin. Of note, PTPRR was down-regulated in ovarian cancers, and ectopic PTPRR re-expression delayed ovarian cancer cell growth both in vitro and in vivo. Using a proximity-based tagging system and RNA-Seq analysis, we identified a signaling nexus that includes PTPRR, α-catenin, β-catenin, E-cadherin, and AT-rich interaction domain 3C (ARID3C) in ovarian cancer. Immunochemical staining of human samples further suggested that PTPRR expression is inversely correlated with disease prognosis. Collectively, our findings indicate that PTPRR functions as a tumor suppressor in ovarian cancer by dephosphorylating and inactivating β-catenin. These results suggest that PTPRR expression might have utility as a prognostic marker for predicting overall survival.

Ovarian cancer is one of the deadliest malignant tumors and the fifth-leading cause of cancer-related death in women from the United States (1, 2). Over the last 2 decades, advances have greatly improved cancer therapy; however, the survival rate of women with ovarian cancer has barely changed (3–5). Thus, further research is needed to understand how different molecular pathways contribute to tumorigenesis of ovarian cancer and to discover potential therapeutic targets.

The Wnt signaling pathway comprises a large family of glycoproteins known mostly for their critical function in embryonic development, including cell fate determination, differentiation, proliferation, and apoptosis (6, 7). As a result, mutations in the Wnt pathway are often linked to birth defects, cancer, and other diseases in humans (7). Several reports have shown that Wnt/β-catenin signaling is frequently dysregulated in ovarian cancers (8–10). In a comprehensive analysis of 47 primary ovarian specimens, the Wnt/β-catenin pathway was defective in nearly half of the samples (11). The key signaling molecule of the canonical pathway, β-catenin, is often mutated in endometrioid ovarian carcinomas (12–14). In serous, clear cell, and mucinous ovarian carcinomas, although gene mutations in the Wnt/β-catenin pathway are rare, hyperactivation of the pathway and β-catenin–targeted genes are still required for ovarian cancer development (10, 15–17). Therefore, the Wnt pathway is investigated as a potential target in the treatment of ovarian cancer, and the molecular mechanisms of aberrant activation in ovarian cancer should be further studied.

Among multiple tiers of regulation, tyrosine phosphorylation plays an important role in controlling the function of β-catenin (18). Two tyrosine residues in β-catenin are the center of this regulation: tyrosine 142 and 654. SRC, Fyn, and FER kinases are responsible for phosphorylating these sites. Upon phosphorylation, the E-cadherin–β-catenin–α-catenin complex collapses at the plasma membrane, and the released β-catenin translocates to the nucleus for its function as a transcriptional factor (19–23). Tyrosine 654 is indispensable for association with E-cadherin (19, 23). More importantly, the phosphorylation status of Tyr-142 of β-catenin determines the switch between the adhesive and the transcriptional functions of β-catenin. α-Catenin and nuclear factor BCL9-2 share an overlapping binding site on β-catenin, which includes the first armadillo repeat, where Tyr-142 resides (22, 24). Either tyrosine phosphorylation or a mutation to glutamic acid, which...
increases a negative charge on residue 142 in β-catenin, promotes binding to BCL9-2 over α-catenin (24). This BCL9-2 binding stabilizes the phosphorylation of β-catenin and facilitates its nuclear translocation and further binding with LEF/TCF proteins, resulting in increased transcription of Wnt/β-catenin target genes (24, 25). Phosphorylation of Tyr-142 of β-catenin thus becomes a reliable marker to illustrate the activation of Wnt/β-catenin signaling and assess the consequences of perturbing this pathway to human disease.

In the current study, using a shRNA-based biochemical screen, we determined that protein tyrosine phosphatase PTPRR,4 which is down-regulated in ovarian cancers, is responsible for tyrosine dephosphorylation of β-catenin on residue 142. Ectopic expression of PTPRR decreases tyrosine phosphorylation of β-catenin, inhibits the β-catenin–mediated transcriptional activation of downstream target genes, and significantly delays ovarian cancer cell proliferation both in vitro and in vivo. Overall, we reported a negative regulatory function of PTPRR in ovarian cancer oncogenesis, and the expression level of the phosphatase could be a good prognostic marker for overall survival of patients.

Results

Aberrant activation of the Wnt/β-catenin pathway in ovarian tumors and ovarian tumor–derived cell lines

Hyperactivation of β-catenin–mediated Wnt signaling is a major contributing factor of ovarian tumorigenesis (17, 26). Phosphorylation of tyrosine 142 of β-catenin provides a feasible marker to quickly screen the activation status of pathways in ovarian cancers, so we used specific pTyr-142 antibody against β-catenin for immunohistochemistry analysis of tissue array including 133 cases of serous carcinoma, 34 mucinous adenocarcinoma, 3 adenocarcinoma, 7 endometrioid adenocarcinoma, 15 metastatic carcinoma, and 8 adjacent normal ovary tissue. Whereas both adjacent normal ovary tissue and ovarian tumor samples showed equivalent expression levels of total β-catenin, the Tyr-142 phosphorylation signal in tumor samples was significantly higher than normal control (Fig. 1, A and B). In total, 192 ovarian tumor samples were assessed: 20 of the samples were pTyr-142 and β-catenin double-negative; 42 samples were β-catenin–positive but pTyr-142–negative; and 130 of the samples were pTyr-142 and β-catenin double-positive (Fig. 1B). The ratio of pTyr-142 β-catenin–positive samples was higher in tumor patients than in adjacent normal controls (Fig. 1B). Moreover, the ratio of pTyr-142 β-catenin–positive tumor samples was increased with grading advancement of the disease (Fig. 1C). However, a similar trend was not observed in terms of the stage of tumor samples (Fig. 1D). The International Federation of Gynecology and Obstetrics (FIGO) stage is classified according to the TNM Classification of Malig-

nant Tumors, which was closely related to the tumor metastasis states. The tumor grade generally refers to the degree of differentiation or maturity of the cells that make up the tumor within the ovarian primary tumors. Because we analyzed the primary tumor samples, we thought that the tumor grade was more relevant than tumor stage in our scenario.

In addition, we did immunoblotting analysis to compare phosphorylation level of Tyr-142 β-catenin in both ovarian tumor samples from patient and normal ovarian tissue control. Four of eight tumor samples showed evidently high pTyr-142 β-catenin level, whereas all six normal ovarian tissues showed trace amounts of pTyr-142 β-catenin (Fig. 1E).

To further evaluate the activation status of the Wnt/β-catenin pathway in ovarian tumors, we compared the distribution of β-catenin in 11 ovarian tumor-derived cell lines with two human ovarian surface epithelial (HOSE) cell lines immortalized by the human papilloma viral oncogenes E6 and E7 as a negative control (27). Sequences of β-catenin from these cell lines were examined before the experiment, and no mutations were detected. We observed a significant increase of nuclear β-catenin in most ovarian cancer cells examined (Fig. 1F). Consistently, phosphorylation of β-catenin on Tyr-142 was also enhanced in these tumor-derived cell lines (Fig. 1G). Moreover, several co-activators of β-catenin, including LEF1, TCF1, TCF3, and TCF4, were selectively up-regulated in most ovarian cancer-derived cell lines, whereas Wnt signaling antagonist SFRP1 was underexpressed compared with normal controls (Fig. 1G).

We also adopted the TOP/FOP reporter system to further confirm Wnt signaling activation in ovarian cancer cell lines. As shown in Fig. 1H, the intensity of TOP luciferase was significantly higher in PA-1, CAOV4, and OVCAR5 compared with HOSE cell lines. Collectively, all of this evidence suggested aberrant activation of the Wnt/β-catenin pathway during the oncogenesis of ovarian cancer.

A protein tyrosine phosphatase screen identified PTPRR as one of the major tyrosine phosphatases responsible for dephosphorylation of β-catenin at Tyr-142

We and others have reported previously that the protein tyrosine kinase FER is a key regulator of Tyr-142 phosphorylation of β-catenin (28, 29). Furthermore, other kinases, including SRC, have also been suggested to modulate this phosphorylation event under different stimulation conditions (19). By using phosphotyrosine antibody, several PTPs have been identified as β-catenin phosphatases (30). Given that multiple tyrosine residues within the β-catenin sequence could be phosphorylated upon stimulation, these findings could not reveal which phosphatase is responsible for dephosphorylation of β-catenin at Tyr-142.

In an initial attempt to address this question, we infected MCF10A cells with shRNA against each individual classical protein tyrosine phosphatase (37 in total) and selected stable cell lines with consistent expression of the designated shRNA. The reasons we use normal breast cells (MCF10A) for screening purpose are as follows: 1) we prefer to use normal cell lines rather than cancer cells, because some genes, like protein tyrosine phosphatases, are usually silenced in cancers; 2) we chose

---

4 The abbreviations used are: PTPRR, protein tyrosine phosphatase receptor type R; FIGO, International Federation of Gynecology and Obstetrics; HOSE, human ovarian surface epithelial; FBS, fetal bovine serum; EGF, epidermal growth factor; qRT-PCR, quantitative RT-PCR; PUP-IT, puylation-based interaction tagging; ARID3C, AT-rich interaction domain 3C; CTG, Cell Titer-Glo; ERK, extracellular signal-regulated kinase; HCD, higher-energy collisional dissociation; FDR, false discovery rate; TBS, Tris-buffered saline; IHC, immunohistochemistry.
PTPRR dephosphorylates and inactivates β-catenin

A.

Adjacent normal ovary tissue

Ovarian tumor

Anti-pY142 β-Catenin

Anti-β-Catenin

B.

β-Catenin

- +

pY142 β-Catenin

- +

Percentage (%)

Adjacent normal ovary tissue

Ovarian tumor

C.

pY142 β-Catenin positive (%)

Grade

1 2 3

(2314) (3514) (8411)

D.

pY142 β-Catenin positive (%)

Stage

I II III IV

(103148) (1810) (1911)

E.

Normal ovary tissue

Ovarian tumor samples

F.

β-Catenin

Lamin B

Tubulin

Nuc

Cyto

G.

Y142 β-Catenin

LEF1

TCF1

TCF3

TCF4

SFRP1

GAPDH

H.

TCTFOP luciferase

p=0.03

p=0.02

p=0.05

Hose 6-5

Hose 11-12

PA1

OVCAR5

CAOV4
MCF10A rather than normal ovarian control HOSE11-12 and HOSE6-3, because both of these ovarian cell lines are very difficult to subject to infection procedures to make stable cell lines for further investigations. For each PTP, two shRNA constructs were applied in this assay.

We collected cell lysates and performed immunoblotting analyses to compare the tyrosine phosphorylation change of β-catenin in the absence and presence of PTP shRNA. Under normal fetal bovine serum (FBS)-containing medium, 8 of 37 classic PTPs showed enhanced tyrosine phosphorylation of β-catenin upon shRNA knockdown: PTPN2, PTPN22, PTPN23, PTPRJ, PTPRK, PTPS31, PTPRR, and PTPRU. We further stimulated cells with EGF to evaluate the function of PTP knockdown on β-catenin phosphorylation, when β-catenin SRC kinases were activated (Fig. 2A). Compared with luciferase shRNA control, shRNA against both PTPN23, whose function in dephosphorylating Tyr-142 of β-catenin has been recently reported by us (31), and PTPRR demonstrated elevated tyrosine phosphorylation level of β-catenin on 142 (Fig. 2B). PCR analysis was also performed to confirm the effectiveness of shRNA knockdown in targeting all of these candidate tyrosine phosphatases (Fig. 2C). These results strongly suggested that PTPRR might be the tyrosine phosphatase controlling the phosphorylation level of β-catenin at Tyr-142.

PTPRR was down-regulated in ovarian carcinoma–derived cell lines, and ectopic re-expression of PTPRR led to significantly delayed cell growth in vitro and tumorigenesis in vivo

Next, we used immunoblotting to compare the expression of PTP proteins between two HOSE cell lines and 11 ovarian carcinoma–derived cell lines. In total, 13 PTP proteins were probed, including all positive hits from previous studies. The expression patterns of these 13 PTPs were divided into three categories: diminished expression, which contained PTPRU, PTPRJ, PTPRF, and PTPN2, PTPN6, PTPN11, PTPN22, PTPRS, and PTPRH; and unchanged expression, including PTPRU, PTPRJ, PTPRF, and PTPN23. We observed that the level of PTPRR was significantly down-regulated, relative to the HOSE control cells, in all ovarian carcinoma–derived cell lines (Fig. 3A).

To further assess the biological consequences of PTPRR loss in ovarian carcinoma–derived cells, we established stable lines (OVCAR5 w/PTPRR and CAOV4 w/PTPRR) in which PTPRR protein was ectopically expressed (Fig. 3, B and D). Ectopic expression of PTPRR-WT, but not DA mutant (substrate-trapping mutant of the phosphatase, lacking phosphatase activity), decreased the phosphorylation level of ERK1/2, a known substrate of the phosphatase (Fig. 3, B and D) (32). Concomitantly, tyrosine phosphorylation of β-catenin, but not its activating kinase SRC, was also decreased in the presence of ectopically expressed tyrosine phosphatase PTPRR (Fig. 3, B and D). Consistently, expression of WT PTPRR significantly decreased the TOP luciferase intensity, implying the inactivation of Wnt signaling (Fig. 3, C and E). We did notice a relatively mild but statistically significant difference between the parental and PTPRR-WT cell lines (Fig. 3C). We reasoned this to the potential functional redundancy of protein tyrosine phosphatases. As shown in Fig. 2B, our shRNA screen identified that knockdown of PTPN2, PTPN23, or PTPN22 could increase the phosphorylation level of β-catenin. Furthermore, restoration of PTPRR expression in ovarian tumor cells delayed cell proliferation (Fig. 3, F and G). These effects were not observed in cells with enzymatically dead trapping mutant of the phosphatase (DA mutant) (Fig. 3, F and G) or cells with SHP1 expression (Fig. 3, H and J), indicating that phosphatase activity of PTPRR was required in cell proliferation regulation.

Our observation that ovarian cancer cells with ectopically expressed PTPRR showed a reduced rate of proliferation prompted us to further investigate its role in vivo. We adopted a xenograft mouse model with subcutaneous injection of either parental or PTPRR-overexpressed OVCAR5 cells to evaluate whether restoration of PTPRR affected the growth of ovarian cancer cells. All cells were engineered with a luciferase cassette so that we could easily monitor tumor growth in vivo. Results showed that ectopic expression of PTPRR-WT, but not DA mutant, significantly delayed xenograft tumor growth (Fig. 4 (A–C) and Fig. S1A). Compared with parental OVCAR5 cells and PTPRR-DA–overexpressed tumors, tumors with PTPRR-WT overexpression showed less positive staining of Ki-67 (Fig. 4, D and E), a standard marker for cell proliferation. Using immunohistochemistry staining, we also observed decreased tyrosine phosphorylation of β-catenin on 142 in tumors with PTPRR-WT overexpression (Fig. 4, D and E). We also used an intraperitoneal injection mouse model to further evaluate the regulatory function of PTPRR in ovarian tumor growth in vivo. Consistent with a previous subcutaneous injection mouse model, OVCAR5 cells with PTPRR-WT overexpression significantly decreased the number of tumor formations in the small intestine (Fig. 4F and Fig. S1B). Mice injected with PTPRR-WT–expressed tumor cells also showed less body weight loss (Fig. 4G). In summary, the restoration of functional PTPRR delays ovarian cancer cell proliferation both in vitro and in vivo.

PTPRR-dephosphorylated β-catenin at Tyr-142 was α-catenin–dependent

SRC, FER, and other tyrosine kinases are key regulators of Tyr-142 phosphorylation of β-catenin. We therefore investigated whether these kinases that induced phosphorylation of β-catenin at Tyr-142 were also dephosphorylated by PTPRR.

**Figure 1. Aberrant activation of the Wnt/β-catenin pathway in ovarian tumors and ovarian tumor–derived cell lines.** A, ovarian cancer with adjacent normal ovary tissue array was immunostained with antibodies against Tyr-142–phosphorylated and total β-catenin. Representative images are shown. B, summary and statistical analysis of immunohistochemistry staining status of ovary cancer tissue array with antibodies against Tyr-142–phosphorylated and total β-catenin. C, ratio analysis of pTyr-142 β-catenin–positive ovary tumor samples at different grades of the disease. D, ratio analysis of pTyr-142 β-catenin–positive ovary tumor samples at different stages of the disease. E, immunoblot analysis of pTyr-142 β-catenin with adjacent normal tissue and ovary tumor tissue. F, cytosolic and nuclear distribution of β-catenin in both control and ovarian carcinoma–derived cell lines. The blots were reprobed for lamin B and tubulin as nuclear and cytosolic markers, respectively. G, total cell lysates from both control and ovarian carcinoma–derived cell lines were immunoblotted for pTyr-142 and total β-catenin, as well as Wnt/β-catenin pathway activation markers LEF1, TC1F, TC1F3, TC1F4, and SFRP1, using GAPDH as a loading control. H, TOP/FOP reporter assay with control and ovarian carcinoma–derived cell lines. Results represent mean ± S.D. (error bars).
Both substrate-trapping mutant (DA) and enzymatically dead mutant (CS) were also included in this study, as indicated. The results demonstrated that WT PTPRR, but not DA mutant, could dephosphorylate β-catenin on Tyr-142 in 293T cells (Fig. 5A). Then we investigated whether PTPRR dephosphorylates β-catenin by direct binding. The co-immunoprecipitation experiment showed that none of the WT, DA mutant, and CS mutant of PTPRR could form a complex with β-catenin (Fig. 5B).

We then concluded that PTPRR dephosphorylation of β-catenin was via indirect binding. It has been reported that E-cadherin, β-catenin, and α-catenin could form a complex at the plasma membrane (19–23). We then used a proximity-based tagging system, PUP-IT (pupylation-based interaction tagging) (33), to identify potential protein–protein interactions between PTPRR and E-cadherin or α-catenin as well as other proteins. A small protein tag, Pup (E), is covalently transferred to proteins that interact with a PafA-fused bait (here PTPRR), enabling transient and weak interactions to be enriched and detected by MS. We first successfully engineered an inducible ovarian cancer cell line expressing Pup (E) upon doxycycline addition. The dephosphorylation function of PafA-fused
PTPRR dephosphorylates and inactivates β-catenin


**PTPRR dephosphorylates and inactivates β-catenin**

PTPRR was also confirmed by Western blotting (Fig. S2A). In total, 41 single-cell clones were established, and clone 9 (Fig. S2B) was chosen for further investigation due to its high efficiency of doxycycline induction. Then we stably expressed PTPRR (WT)-PafA or PTPRR (DA)-PafA in these inducible cells and identified Pup (E)-labeled proteins as the potential substrates for the phosphatase. The results have been deposited to the ProteomeXchange Consortium (PXD015352). Consistent with the co-immunoprecipitation experiment, we did not observe any interaction between β-catenin and either WT or DA mutant of PTPRR. We did observe strong binding between PTPRR and MAPK1, the known substrates of the phosphatase; however, the trapping mutant of the phosphatase did not show preferential binding to this substrate. We also found that α-catenin (CTNNA1) had similar strong binding to both WT and DA mutant of PTPRR (Table S2).

We performed a biochemical pulldown assay in OVCAR5 cells to further confirm the results from the PTPRR PUP-IT experiment. Using a reciprocal immunoprecipitation assay, we found that PTPRR formed a complex with α-catenin (Fig. 5, C and D). In line with previous reports, α-catenin also formed a complex with E-cadherin and β-catenin in OVCAR5 cells (Fig. 5, E and F). These results implied that α-catenin may mediate the recruitment of PTPRR near β-catenin for subsequent dephosphorylation.

We then used shRNA to knock down α-catenin in both parental and PTPRR-WT–expressed OVCAR5 cells to examine whether the recruitment of PTPRR by α-catenin was required for β-catenin dephosphorylation on site 142 (Fig. 5, G and H). First, PTPRR expression significantly reduced the phosphorylation level of Tyr-142 β-catenin (Fig. 5H, lane 1 versus lane 4). Second, in parental OVCAR5 cells with no PTPRR expression, loss of α-catenin had minimal effect on tyrosine phosphorylation of β-catenin (Fig. 5H, lane 1 versus lanes 2 and 3). On the contrary, in OVCAR5 cells with ectopic PTPRR-WT expression, tyrosine phosphorylation of β-catenin on Tyr-142 was increased upon α-catenin knockdown (Fig. 5H, lane 4 versus lanes 5 and 6). Third, cell fractionation analysis demonstrated nuclear accumulation of pTyr-142, and total β-catenin was reduced by PTPRR in an α-catenin–dependent manner (Fig. S3). Taken together, our data demonstrated that α-catenin could form a complex with E-cadherin, β-catenin, and PTPRR, and its association with PTPRR is required for dephosphorylation and nuclear accumulation of β-catenin by the phosphatase.

ARID3C was identified as one of the major β-catenin downstream targets in controlling ovarian cancer cell proliferation

Next, we conducted RNA-Seq to further evaluate the impact of PTPRR-mediated β-catenin dephosphorylation on changes in transcription profiling in both ovarian cancer cells and xenograft tumors. Results from OVCAR5 cells with or without ectopic expression of either PTPRR-WT or DA mutant are illustrated in Fig. 6A (and GEO database entry GSE135220), with -fold change ≥ 2^(−0.5) or ≥ 2^(0.5) highlighted. Genes meeting the following criteria were defined as responsive genes: (i) -fold change ≥ 2^(−0.5) or ≥ 2^(0.5) in both parental OVCAR5 and PTPRR-DA–overexpressed OVCAR5 cells; (ii) 2^(−0.5) ≤ -fold change ≤ 2^(0.5) in PTPRR-WT–overexpressed OVCAR5 cells. The experiment was repeated twice. In total, 1,267 genes were identified (Fig. 6E), and KEGG database analysis of these genes suggested that the Wnt signaling pathway was significantly enriched (Fig. 6B).

We did the same RNA-Seq analysis in xenograft tumor samples (Fig. 6C and GEO database entry GSE135220). In total, 1,817 candidate genes that were significantly changed in tumors with PTPRR-WT expression were identified (Fig. 6E). To pinpoint PTPRR responsive genes, we analyzed RNA-Seq data from both cell lines and xenograft tumor samples and defined candidates as the overlapped significantly changed genes. In total, 97 PTPRR responsive genes were identified and illustrated in Fig. 6D. All of these genes were further filtered by a previously published ChiP-Chip data set of β-catenin (34). Through all of these analyses, ARID3C, PBXIP1, and DVL3 were demonstrated as β-catenin–targeted genes, and their expression levels were regulated by PTPRR in ovarian cancer cells (Fig. 6E).

We performed qRT-PCR to confirm the expression patterns of these three genes in OVCAR5 cells with or without ectopic expression of either PTPRR-WT or DA mutant, as well as in xenograft tumor samples with injection of either parental, PTPRR-WT, or PTPRR-DA–expressed OVCAR5 cells (Fig. 6, F–H). Expression patterns of the three genes met the criteria of “responsive gene” (the expression level must be significantly down-regulated in cells with PTPRR-WT overexpression while showing no significant difference in cells with PTPRR-DA overexpression), with ARID3C (AT-rich interactive domain-containing protein 3C) as the best fit (Fig. 6F). Furthermore, we did ChiP-PCR analysis to further pinpoint the binding region of β-catenin on the promoter of ARID3C (Fig. 6F). The result was...
PTPRR dephosphorylates and inactivates β-catenin.
**PTPRR dephosphorylates and inactivates β-catenin**

consistent with the previous report (34), indicating that the transcriptional regulation of ARID3C was under the control of β-catenin.

To further evaluate the function of ARID3C in ovarian cancer cell proliferation, we performed shRNA knockdown of ARID3C in both OVCAR5 cell lines with or without ectopic PTPRR-WT (Fig. 6L), followed by a Cell Titer-Glo (CTG) assay. We found that ARID3C knockdown could robustly inhibit cell proliferation only in parental OVCAR5 cells and not in cells with ectopic PTPRR-WT expression (Fig. 6K), revealing ARID3C as one of the major downstream target genes of the PTPRR-β-catenin signaling axis in controlling ovarian cancer cell proliferation.

**PTPRR was underexpressed in ovarian cancers, and its down-regulation was inversely correlated with prognosis**

In support of these functional studies of PTPRR in ovarian cancer cells, we searched the Human Protein Atlas to compare the protein expression level of the phosphatase between normal ovary and malignant ovarian carcinomas. In line with our findings, we observed lower expression of PTPRR in ovarian cancer patient samples (Fig. 7A); in contrast, the phosphatase was highly expressed in normal ovary tissue (Fig. 7A).

We collected normal fallopian tube and ovary samples (n = 12) as well as ovarian tumor samples (n = 18) to further explore the expression differences of PTPRR and its impact on Tyr-142 phosphorylation of β-catenin by immunohistochemistry (Fig. 7B). Consistent with the results obtained from the Human Protein Atlas database, the expression level of PTPRR was significantly decreased in ovarian cancer patient samples compared with normal control (Fig. 7C). Furthermore, we observed a higher extent of phosphorylation on β-catenin within the patient cohort (Fig. 7D), and a significant negative correlation between PTPRR expression and phosphorylation intensity of Tyr-142 β-catenin was present among 18 tumor samples (Fig. 7E).

Finally, we analyzed clinical data from over 1,000 ovarian cancer patients (http://kmplot.com/analysis/)5 (58) to further investigate the relationship between PTPRR expression and tumor progression. The data indicated that expression of PTPRR was a good prognostic indicator for overall survival parameters of the patient (Fig. 7F). The extent of separation was even significant within patient cohorts suffering from grade 1 and grade 2 disease (Fig. 7G).

**Discussion**

The core Wnt/β-catenin signaling pathway signal transduction cascade is one of the main regulators of development throughout the animal kingdom (35). Mutated Wnt pathway components are causative in multiple types of cancers (36–38). However, the frequencies of mutations in the Wnt/β-catenin pathway are relatively low in serous, clear cell, and mucinous ovarian carcinomas (11). But the components of the pathway and β-catenin targeted genes are still important in ovarian cancer development (10). Phosphorylation of two tyrosine residues in β-catenin, tyrosine 142 and 654, activates the Wnt/β-catenin pathway (20). Tyrosine kinases, including SRC, Fyn, and FER, are responsible for phosphorylation of these sites (19–23). Whereas several PTPs have been suggested as β-catenin phosphatases (30), the identity of the phosphatase that is responsible for dephosphorylation of β-catenin at Tyr-142 is still missing, especially within the ovarian cancer context.

In this study, we revealed aberrant activation of the Wnt/β-catenin pathway in ovarian patient samples and ovarian tumor-derived cell lines. Through selection with shRNA against all 37 classic protein tyrosine phosphatases, we identified PTPRR as one of the major tyrosine phosphatases responsible for dephosphorylation of β-catenin at Tyr-142. We found that PTPN23 knockdown also up-regulated the phosphorylation of Tyr-142 β-catenin (Fig. 2B), but the expression of PTPN23 was not down-regulated in ovarian cancer cell lines (Fig. 3A). Thus, we focused on PTPRR in our studies. The PTPRR gene maps to chromosome 12, and the protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. By methylomic approaches, PTPRR was discovered to be methylation-silenced in invasive cervical cancer (39). In acute myeloid leukemia patients, somatic mutations of PTPRR are identified using a whole-genome sequencing approach (40). Expression of PTPRR was reported to be low in oral squamous cell carcinoma (41), prostate cancer cells (42), and pancreatic cancer patient samples (43). In addition, ectopic expression of PTPRR by site-specific lentiviral injections in a mouse model resulted in increased ERK dephosphorylation, which revealed that ERK might be one of the substrates of PTPRR (44). Our study showed that decreased PTPRR expression–induced hyperactivation of β-catenin was required for ovarian cancer oncogenesis. All of these studies and ours reinforce the importance of PTPRR in tumor progression and its tumor suppressor functions. It is thus essential to identify the physiological substrates of PTPRR and the relevant signaling pathways it regulates.

We next combined PTP substrate trapping strategy with the PUP-IT system to identify the potential binding partner of PTPRR. Consistent with the co-immunoprecipitation experiment, we did not observe any interaction between β-catenin and PTPRR. However, α-catenin showed similar strong binding to either WT or DA mutant of PTPRR. By knocking down α-catenin, we found that the dephosphorylation of Tyr-142 β-catenin by PTPRR was suppressed (Fig. 5H), indicating the
PTPRR dephosphorylates and inactivates β-catenin

A. 

|                | SRC | PTPRR-WT | PTPRR-DA |
|----------------|-----|----------|----------|
| pY142 β-Catenin| -   | +        | +        |
| β-Catenin      | -   | +        | +        |
| pY416 SRC      | -   | +        | +        |
| SRC            | -   | -        | +        |
| PTPRR          | -   | -        | +        |
| Actin          | -   | -        | +        |

B. 

|                | Input | IP: Myc |
|----------------|-------|--------|
| β-Catenin      | -     | +      |
| SRC            | -     | +      |
| PTPRR-WT-Myc   | -     | -      |
| PTPRR-DA-Myc   | -     | +      |
| PTPRR-CS-Myc   | -     | -      |
| β-Catenin      | -     | -      |
| PTPRR          | -     | -      |
| SRC            | -     | -      |
| Actin          | -     | -      |

C. 

|                | Input | IP: anti-Myc (PTPRR) |
|----------------|-------|----------------------|
| α-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| β-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| E-Cadherin     | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| PTPRR          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| Actin          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |

D. 

|                | Input | IP: anti-α-Catenin |
|----------------|-------|-------------------|
| α-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| β-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| E-Cadherin     | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| PTPRR          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| Actin          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |

E. 

|                | Input | IP: anti-E-Cadherin |
|----------------|-------|---------------------|
| E-Cadherin     | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| β-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| α-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| PTPRR          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| Actin          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |

F. 

|                | Input | IP: anti-β-Catenin |
|----------------|-------|-------------------|
| β-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| α-Catenin      | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| E-Cadherin     | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| PTPRR          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |
| Actin          | OVCAR-5 | Empty vector | PTPRR WT | PTPRR DA |

G. 

|                | Relative Expression Level | CTNN1A1 |
|----------------|---------------------------|---------|
| OVCAR5         | shCon | shCTNN1A1-1 | shCTNN1A1-2 |

H. 

|                | O5-LUC | O5-LUC-PTPRR-WT |
|----------------|--------|----------------|
| sh α-Catenin   | -      | -              |
| pY142 β-Catenin| 1.00   | 0.93           |
| β-Catenin      | 1.08   | 0.86           |
| PTPRR          | -      | 0.57           |
| Actin          | -      | 0.68           |

J. Biol. Chem. (2019) 294(48) 18306 –18323
PTPRR dephosphorylates and inactivates β-catenin

necessity of α-catenin during this dephosphorylation. We also confirmed that β-catenin formed a complex with α-catenin and E-cadherin in ovarian cancer cell lines by immunoprecipitation. Thus, we concluded that PTPRR dephosphorylation of β-catenin is α-catenin–dependent.

With RNA-Seq and ChIP-PCR analysis, we found that ARID3C is a novel downstream target of the PTPRR-β-catenin cascade in ovarian cancer cells. ARID3C was recently characterized as one of the AT-rich interactive domain (ARID) family proteins featuring a highly conserved, helix-turn-helix DNA-binding domain (45, 46). Proteins with this domain bind to the major groove of DNA and are involved in functions ranging from chromatin remodeling to cell cycle control (45, 47). Although studies on ARID3C are still limited, its two closely related paralogues, ARID3A and ARID3B, are reported to be associated with tumorigenesis (48–50). In particular, ARID3A and ARID3B, and ectopic re-expression of the phosphatase led to significantly delayed ovarian cancer cell growth \textit{in vitro}. The results of this study suggest that the expression level of the phosphatase could be a good prognostic marker for overall survival of patients.

\textbf{Experimental procedures}

\textit{Tissue array analysis}

A commercial ovarian tissue array was used for this analysis (OV2001a, Biomax US). This tissue array includes both eight adjacent normal ovary tissues, which are widely used as normal control, and ovarian tumors, including 133 cases of serous carcinoma, 34 mucinous adenocarcinoma, 3 adenocarcinoma, 7 endometrioid adenocarcinoma, and 15 metastatic carcinoma. This tissue array also includes information about TNM and FIGO classification and staging of tumors of the ovary, fallopian tube, and primary peritoneal carcinoma. Antibodies used in this staining were pTyr-142 and total β-catenin (CP1081 and CM1181, ECM Bioscience).

\textbf{PTP shRNA library construction and infection}

The details for PTP shRNA library construction, including shRNA sequences, were described by Lin \textit{et al.} (54). In brief, a retroviral expression vector, pMLP (MSCV-based vector expressing shRNA in a miR30 context), was used to construct this shRNA library. This vector contains puromycin resistance marker and an EGFP marker for stable cell line selection. The RNAi Codex program (59) was applied to generate shRNA sequence for each protein tyrosine phosphatase. shRNA retrovirus was generated in Phoenix-Ampho packaging cells by co-transfecting plasmids, including pMLP, VSVG, and the pCLe-Ampo retrovirus packaging vector, at a ratio of 3:1:1. 24 h after transfection, recombinant retrovirus supernatants were harvested. The cleared supernatants were then incubated with MCF10A cells in the presence of Polybrene (8 mg/ml final concentration). 24 h after infection, cells were placed under puromycin selection (2 mg/ml final concentration) for generating a PTP knockdown stable cell line.

MCF10A cells were lysed in radioimmunoprecipitation buffer (50 mm Tris-Cl, pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 50 mm NaF, 1 mm Na3VO4, 10% glycerol, protease inhibitor mixture from Roche Applied Science) at 4 °C for 30 min.

\textbf{Cell culture}

Ovarian carcinoma–derived cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 μg/ml). Normal HOSE11-12 and HOSE6-3 control cell lines were grown in 199/MCDB 105 (1:1) medium containing 10% FBS. Cells were maintained at 37 °C in an atmosphere of 5% CO2.

\textbf{Cell transfection}

PTPRR cDNA (NM_002849 658aa) was used in this study. The DA mutant of PTPRR was a point mutation at D554A based on PTPRR-WT cDNA. The CS mutant of PTPRR was a point mutation at C588S based on PTPRR-WT cDNA. These cDNAs were cloned into the expression plasmids pCDNA3.1 and pWZX.

Cells were transfected with plasmids by using transfection reagent Mirus (TransIT-2020, Mirus Bio), following the supplier’s guidance. Briefly, cells were plated in a 6-well plate on the first day. TransIT:DNA complexes were prepared by combining Opti-MEM 1 reduced-serum medium, plasmid DNA, and TransIT® reagent and adding to cells on the second day. Cells were harvested for further studies 24 h after the transfection.

\textbf{TOP/FOP reporter assay}

We transfected cells with TOP or FOP flash plasmids along with SV40-\textit{Renilla} plasmid (control for transfection) using transfection reagent Mirus (TransIT-2020, Mirus Bio). Two days after transfection, we detected luciferase activity using the
PTPRR dephosphorylates and inactivates β-catenin
PTPRR dephosphorylates and inactivates β-catenin

Dual-Luciferase reporter assay system (FR201-01, Transgen Biotech) according to the manufacturer’s protocol.

Cell proliferation assay

The Cell Titer-Glo (CTG) luminescent cell viability assay (Promega) was used to evaluate the role of PTPRR in ovarian cancer cell proliferation. In brief, 1.5 × 10^5 cells (OVCAR5 and CAOV4) per well were seeded in a 96-well plate and grown for the indicated time intervals. CTG reagent was added to each well and mixed for ~15 min on an orbital shaker to induce cell lysis, followed by luminescence reading. Results represent mean ± S.E. from three independent experiments.

Cell fractionation assay

We used the NE-PER nuclear and cytoplasmic extraction reagents kit (catalog no. 78833) to extract nuclear and cytosolic compartments of control and ovarian cancer cell lines, following the manufacturer’s protocol. Lamin B and tubulin were used as nuclear and cytosolic markers, respectively.

PUP-IT mass spectrometry

The experimental procedure was modified based on a previous study (33). To generate iPUP (inducible Pup) cell lines, we produced lentivirus with the PUP (E) plasmid (Bio-Pup (E)-IRE-BFP within the Tet-On system) and infected OVCAR5 cells for 48 h. 2 μg/ml doxycycline (Selleck, S4136) was added into the culture medium for another 24 h. After that, BFP-positive cells were sorted into 96-well plates for single clone selection. Two weeks later, each clone was examined for BFP expression by flow cytometry with or without doxycycline. The expression of Bio-Pup (E) in BFP-positive cells was also confirmed by Western blot analysis.

To further stably express PTPRR (WT)-PafA or PTPRR (DA)-PafA in iPUP OVCAR5 cells, we subcloned PTPRR-WT or -DA, respectively, into the PafA-IRE-BFP plasmid. Each plasmid was packed into a lentivirus and then transduced into iPUP OVCAR5 cells for 48 h. GFP-positive cells were sorted by flow cytometry. The expression of PTPRR (WT)-PafA and PTPRR (DA)-PafA was confirmed by Western blot analysis.

PTPRR (WT)-PafA or PTPRR (DA)-PafA expressed iPUP OVCAR5 cells were grown to a cell density of about 75% on 10-cm dishes. We followed the protocol established in the study by Liu et al. (33). We used trypsin to generate peptides. To prepare PUP-IT samples for MS analysis, we used doxycycline induction, biotin labeling, cell lysis, streptavidin magnetic beads pulldown, trypsin digestion, and peptide cleaning.

An Easy-nLC 1000 system coupled to a Q Exactive HF (both from Thermo Scientific) was used to separate and analyze peptides (33). About 1 μg of peptides were isolated in an EASY-Spray C18 column (75 μm × 50 cm, 2 μm, 100 Å, Thermo Scientific) at a flow rate of 250 nl/min at 50 °C. Mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in 98% acetonitrile) were used to establish a 60-min gradient composed of 1 min of 4% B, 48 min of 4–26% B, 1 min of 26–30% B, 1 min of 30–70% B, and 9 min of 70% B. Electrospray was set to 2.35 kV for ionizing peptides. The following conditions were used to acquire a full MS spectrum (300–1400 m/z range): resolution of 120,000 at m/z 200 and a maximum ion accumulation time of 20 ms. Dynamic exclusion was set to 30 s. Resolution for HCD MS/MS spectra was 30,000 at m/z 200. The automatic gain control settings of MS1 and MS2 were 3E6 and 1E5, respectively. The 20 most intense ions above a 3.3E4 count threshold were selected for fragmentation by HCD with a maximum ion accumulation time of 60 ms. An isolation width of 1.6 m/z units was used for MS2. We excluded single and unassigned charged ions from MS/MS. Normalized collision energy was 25% for HCD.

The raw data were processed and searched with MaxQuant version 1.5.4.1 with MS tolerance of 4.5 ppm and MS/MS tolerance of 20 ppm. The Uniprot human protein database (release 2016_07, 70,630 sequences) and a database for proteomics contaminants from MaxQuant were used for database searches. Reversed database searches were used to evaluate false discovery rate (FDR) of peptide and protein identifications. Two missed cleavage sites of trypsin were allowed. Oxidation (M), pyro-Glu (Gln at peptide N terminus), acetyl (Protein N-term), deamidation (NQ), and GGE (K) were set as variable modifications. We set the FDR of both peptide identification and protein identification to 1%. We also enabled the options of “Second peptides,” “Match between runs,” and “Dependent peptides.” Label-free quantification was used to quantify the difference in protein abundances between different samples.

We compared the difference in terms of binding proteins between OVCAR5 cells with PTPRR-WT expression and cells with PTPRR-DA expression. To obtain reliable quantification measurement, each group sample was triplicated. To analyze...
the different proteins between OVCAR5 cells with PTPRR-WT and PTPRR-DA expression, we calculated the -fold change of LFQ intensity and used a t test to calculate the p value. -Fold change >2 or <0.5 and a p value <0.05 were regarded as significantly different proteins. Then the data were plotted using GraphPad Prism.

**Immunoblotting and immunoprecipitation**

Cell extracts were prepared in 1% Nonidet P-40 lysis buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 50 mM NaF, 1 mM Na3VO4, 10% glycerol, and protease inhibitor mixture from Roche Applied Science) at 4 °C for 30 min. Total protein concentration was determined using the Bradford

---

**Figure 7.** PTPRR was significantly underexpressed in ovarian cancers, and its down-regulation was inversely correlated with prognosis. **A,** representative tissue microarray cores showing diminished expression of PTPRR in malignant ovarian carcinoma sections compared with normal ovary. Data were taken from the Human Protein Atlas. **B,** summary of the immunohistochemistry results for PTPRR protein. **C,** immunohistochemistry staining (pTyr-142 β-catenin and PTPRR) of normal (n = 12) and ovarian carcinoma (n = 18) samples. Results represent mean ± S.D. (error bars). **D,** statistical analysis of PTPRR H score between normal (n = 12) and ovarian carcinoma (n = 18) samples. Results represent mean ± S.D. **E,** correlation analysis of pTyr-142 β-catenin and PTPRR H score in ovarian carcinoma (n = 18) samples. **F,** PTPRR expression was stratified as high versus low against median expression. Overall survival within patients identified at disease grades 1 and 2 was further analyzed using km Plotter (http://kmplot.com/analysis/) (58). **G,** PTPRR expression was stratified as high versus low against median expression. Overall survival within patients identified at disease grades 1 and 2 was further analyzed using km Plotter (http://kmplot.com/analysis/) (58).
assay. Proteins were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked in 5% BSA in TBST (TBS/Tween 20; 20 mM Tris/HCl, pH 7.6, 136 mM NaCl, and 0.1% Tween 20) and incubated at 4 °C overnight with primary antibody. Proteins were detected with horseradish peroxidase– conjugated secondary antibodies (Jackson Laboratory) and ECL (Pierce). The primary antibodies used in this study were as follows: pTyr-142 β-catenin (CP1081, ECM Bioscience) diluted 1:500, β-catenin (CM1181, ECM Bioscience) diluted 1:500, α-catenin (A6535, Abclonal) diluted 1:1,000, lamin B (sc-6216, Santa Cruz Biotechnology, Inc.) diluted 1:500, γ-tubulin (T6557, Sigma) diluted 1:1,000, actin (A2066, Sigma) diluted 1:10,000, GAPDH (NB300-221E, Novus Biologicals) diluted 1:1,000, LEF1 (catalog no. 2230, Cell Signaling Technology) diluted 1:1,000, TCF1 (catalog no. 2203, Cell Signaling Technology) diluted 1:1,000, TCF3 (catalog no. 2883, Cell Signaling Technology) diluted 1:1,000, SFRP1 (catalog no. 3534, Cell Signaling Technology) diluted 1:1,000, pERK1/2 (Thr-202/Tyr-204) (catalog no. 4377, Cell Signaling Technology) diluted 1:1,000, ERK1/2 (catalog no. 4695, Cell Signaling Technology) diluted 1:1,000, PTPN22 (catalog no. 3759, Cell Signaling Technology) diluted 1:1,000, PTPN11 (catalog no. 3397, Cell Signaling Technology) diluted 1:1,000, pTyr-416 Src (catalog no. 2101, Cell Signaling Technology) diluted 1:1000, pTyr-527 Src (catalog no. 2105, Cell Signaling Technology) diluted 1:1,000, Src (catalog no. 2110, Cell Signaling Technology) diluted 1:1,000, E-cadherin (catalog no. 3195, Cell Signaling Technology) diluted 1:1,000, PTPRR (PA5-29243, Invitrogen) diluted 1:1,000, PTPRR (catalog no. 29243, Invitrogen), PTPRS (AF3430, R&D Systems) diluted 1:1,000, PTPRU (MAB7475, R&D Systems) diluted 1:1,000, PTPRU (610350, BD Biosciences) diluted 1:1,000, PTPRU (610350, BD Biosciences) diluted 1:1,000, and PTPN22 (H00026191-M01, Abnova) diluted 1:1,000. Primary antibodies, including PTPRM, PTPN2, and PTPRJ, were gifts from Prof. N. K. Tonks (Cold Spring Harbor Laboratory). Mutant of PTPRR were used for RNA-Seq and bioinformatics analysis. We aligned the reads to hg19 using TopHat2, and gene counts were calculated by htseq-count tools.

For immunoprecipitation, precleared cell extracts were incubated with the indicated antibody for 4 h in a cold room with rotation followed by 1 h of pulldown by 1:1 Protein A/G-agarose beads. Immunoprecipitates were washed with lysis buffer three times before electrophoresis.

**ChIP-PCR**

OVCAR5 cells or OVCAR5 cells expressing WT or trapping mutant of PTPRR were cross-linked with 1% formaldehyde for 5 min at room temperature, lysed by SDS lysis buffer, and sonicated to generate DNA fragments with an average size of 500 bp. After preclearing with Protein A/G beads, antibodies against β-catenin (610154, BD Biosciences) or control mouse IgG was added to cell lysate and incubated at 4 °C overnight. DNA cross-linked with β-catenin was pulled down with Protein A/G beads and washed and purified with the MinElute PCR purification kit (catalog no. 28004, Qiagen). Aliquots of CHIP-enriched DNA and whole-cell lysate DNA were subjected to PCR analyses.

**qRT-PCR**

Total RNAs were prepared as described previously (6, 55) and retrotranscribed into first-strand cDNA using the first-strand synthesis system following the manufacturer’s protocol (catalog no. 1708840, Bio-Rad). qRT-PCR was performed using an ABI 7500 sequence detection system (PerkinElmer Life Sciences). Primer sequences are listed in Table S1.

**Gene knockdown using shRNAs**

Lentivirus-mediated delivery of shRNAs directed against ARID3C and CTNNA1 (α-catenin) were performed as described previously (55). shRNAs were packaged in lentiviral particles by co-transfection with packaging plasmids into HEK-293T cells, and the filtered cell culture supernatant was then used to infect cells. The shRNA sequences are listed in Table S1.

**RNA-Seq and bioinformatics analysis**

Total RNAs from OVCAR5 cells, OVCAR5 cells expressing WT or trapping mutant of PTPRR as well as xenograft tumors from OVCAR5 cells, or OVCAR5 cells expressing WT or trapping mutant of PTPRR were used for RNA-Seq analysis. We aligned the reads to hg19 using Tophat2, and gene counts were calculated by htseq-count tools.

**Animal work**

All study protocols involving mice were approved by the institutional animal care and use committee of ShanghaiTech University and conducted in accordance with governmental regulations of China for the care and use of animals.

In the subcutaneous injection model, 1 × 10^6 OVCAR5 cells or OVCAR5 cells expressing WT or trapping mutant of PTPRR were suspended in 100 μl of 1:1 mixture with Dulbecco’s modified Eagle’s medium and growth factor-reduced Matrigel (BD Biosciences) and subcutaneously injected into nude mice. All cells were engineered with a luciferase expression cassette. Subcutaneous tumor growth was monitored periodically by injecting 10 μl of 15 mg/kg d-luciferin (PerkinElmer Life Sciences) intraperitoneally and imaging the animal using a Xenogen imager (Xenogen IVIS-200 optical in vivo imaging system). Tumor volume (formula: volume = width^2 × length/2; in mm^3) and weight (g) of all subcutaneous tumors were measured.

In the intraperitoneal injection model, 5 × 10^6 OVCAR5 cells or OVCAR5 cells expressing WT, DA mutant of PTPRR, or SHP1 were suspended in 100 μl of 1:1 PBS and injected into the peritoneum (body cavity) of nude mice at 6 weeks. Mice were analyzed 6 weeks after injection.

**Immunohistochemistry staining**

Tissues were fixed in 10% buffered formalin for 24 h, followed by a gentle wash and transfer to PBS. Then paraffin-embedded tissues were sectioned to 6-μm-thick, placed on charged glass slides, and stained with hematoxylin and eosin or appropriate immunohistochemical stains. Antigen retrieval was performed by incubating the slides in 0.01 mol/liter citric acid buffer (pH 6.0) at 95 °C for 15 min. Slides were then
allowed to cool to room temperature for 20 min in a citric acid buffer. After the slides were washed with deionized water, they were transferred to TBS (pH 7.4) for 5 min. Slides were counterstained in Mayer’s hematoxylin, dehydrated, cleared, and coverslipped. Negative control slides were run without primary antibody. Control slides known to be positive for each antibody were incorporated. Antibodies used in this staining were pTyr-142 and total β-catenin (ECM Bioscience) and PTPRR (Invitrogen).

Sections were first blocked with 5% normal horse serum and 1% BSA (in TBS) for 1 h at room temperature, and then the primary antibodies were diluted, as suggested by the manufacturer, and incubated overnight at 4 °C. Following three 10-min washes with TBS, sections were incubated with biotinylated secondary antibody for 30 min at room temperature and rinsed with TBS three times for 10 min. Finally, the sections were treated with diaminobenzidine for 3 min and rinsed with distilled water to elude the reaction, mounted on gelatin-coated slides, air-dried, dehydrated with 70–100% alcohol, cleared with xylene, and coverslipped for microscopic observation. After examination of all immunohistochemical and special stains, stained slides were digitally scanned using the Aperio ScanScope software. Staining strength was classified into three levels.

H score was used for statistical analysis and calculated as positive staining percentage multiplied by staining strength (56). Briefly, all specimens were evaluated in a blinded setting to evaluate staining intensity of analyzed cells (on a scale of 0–3) and the fraction of cells staining at each intensity. We adopted a scoring system to calculate the score of intensity times the percentage of the stained tumor cells. For sections with analyzable tumor cells, staining intensity was scored in four categories: no staining (0), weak staining (1+), intermediate staining (2+), between 1+ and 3+, and strong staining (3+). The percentages of tumor cells showing the different staining intensities were assessed visually. We used the prospectively collected IHC data to generate IHC scores on a continuous scale of 0–300. By integration of the data relating to the intensity and frequency of staining, the IHC score was calculated with the formula, 1 × (percentage of cells staining weakly (1+)) + 2 × (percentage of cells staining moderately (2+)) + 3 × (percentage of cells staining strongly (3+)).

Author contributions—Y. W. data curation; Y. W., J. Z., Z. W., and S. C. investigation; Y. W. and G. F. writing-original draft; Y. W., M. Z., and G. F. project administration; J. C. and D. L. resources; W. L., Y. Z., L. H., L. Z., and Y. Y. formal analysis; P. H. methodology; M. Z., Y. Y., D. L., and G. F. supervision; G. F. funding acquisition.

Acknowledgments—We thank Prof. Nicholas K. Tonks (Cold Spring Harbor Laboratory) for reagent support for protein tyrosine phosphatase research in this study. We also thank Dr. Haoping Wang (ShanghaiTech University) for helpful comments in the preparation of the manuscript.

References
1. Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., and Siegel, R. L. (2018) Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68, 284–296 CrossRef Medline
2. Siegel, R. L., Miller, K. D., and Jemal, A. (2018) Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 CrossRef Medline
3. McGuire, W. P. (2009) Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J. Clin. Oncol. 27, 4633–4634 CrossRef Medline
4. Binaschi, M., Simonelli, C., Gosò, C., Bigioni, M., and Maggi, C. A. (2011) Maintenance therapy in ovarian cancer: molecular basis and therapeutic approach. Exp. Ther. Med. 2, 173–180 CrossRef Medline
5. Coleman, M. P., Forman, D., Bryant, H., Butler, J., Rachet, B., Mariné, C., Nur, U., Tracey, E., Coory, M., Hatcher, J., McGahan, C. E., Turner, D., Marrett, L., Gjerstorff, M. L., Johannessen, T. B., et al. (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127–138 CrossRef Medline
6. Rey, T., and Clevers, H. (2005) Wnt signalling in stem cells and cancer. Nature 434, 843–850 CrossRef Medline
7. Clevers, H. (2006) Wnt/β-catenin signaling in development and disease. Cell 127, 469 – 480 CrossRef Medline
8. Wang, H. X., Tekpetey, F. R., and Kidder, G. M. (2009) Identification of WNT/PTPERR signaling pathway components in human cumulus cells. Mol. Hum. Reprod. 15, 11–17 CrossRef Medline
9. Oksjoki, S., Söderström, M., Inki, P., Vuorio, E., and Anttila, L. (2005) Molecular profiling of polycystic ovaries for markers of cell invasion and matrix turnover. Fertil. Steril. 83, 937–944 CrossRef Medline
10. Boyer, A., Goff, A. K., and Boerboom, D. (2010) WNT signaling in ovarian follicle biology and tumorigenesis. Trends Endocrinol. Metab. 21, 25–32 CrossRef Medline
11. Wu, R., Zhai, Y., Fearon, E. R., and Cho, K. R. (2001) Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 61, 8247–8255 CrossRef Medline
12. Dubau, L. (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9, 1191–1197 CrossRef Medline
13. McConney, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L. M., Wiegand, K. C., McAlpine, J. N., Shah, S. P., Lee, C. H., Goodfellow, P. J., Gilks, C. B., and Huntsman, D. G. (2014) Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod. Pathol. 27, 128–134 CrossRef Medline
14. Sægusa, M., and Okayasu, I. (2001) Frequent nuclear β-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J. Pathol. 194, 59–67 CrossRef Medline
15. Rask, K., Nilsson, A., Brännström, M., Carlsson, P., Hellberg, P., Janson, P. O., Hedlin, L., and Sundfeldt, K. (2003) Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β. Br. J. Cancer 89, 1298–1304 CrossRef Medline
16. Takebe, N., Harris, P. J., Warren, R. Q., and Ivy, S. P. (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8, 97–106 CrossRef Medline
17. Barbolina, M. V., Burkhalter, R. J., and Stack, M. S. (2011) Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem. J. 437, 1–12 CrossRef Medline
18. Brembeck, F. H., Rosário, M., and Birchmeier, W. (2006) Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr. Opin. Genet. Dev. 16, 51–59 CrossRef Medline
19. Roura, S., Miravet, S., Piedra, J., García de Herreros, A., and Duñach, M. (1999) Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J. Biol. Chem. 274, 36734–36740 CrossRef Medline
20. Piedra, J., Miravet, S., Cañedo, J., Pálmer, H. G., Heisterkamp, N., García de Herreros, A., and Duñach, M. (2003) p120 catenin-associated Fer and Fyn tyrosine kinases regulate β-catenin Tyr-142 phosphorylation and β-catenin-α-catenin interaction. Mol. Cell. Biol. 23, 2287–2297 CrossRef Medline
21. Aberle, H., Schwartz, H., Hoschuetzky, H., and Kemler, R. (1996) Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to α-catenin. J. Biol. Chem. 271, 1520–1526 CrossRef Medline
PTPRR dephosphorylates and inactivates β-catenin

22. Pokutta, S., and Weis, W. I. (2000) Structure of the dimerization and β-catenin-binding region of α-catenin. Mol. Cell 5, 533–543 CrossRef Medline

23. Mishra, J., Das, J. K., Kumar, N. (2017) Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin. J. Biol. Chem. 292, 16406–16419 CrossRef Medline

24. Brembeck, F. H., Schwarz-Romond, T., Bakkers, J., Wilhelm, S., Hammer-schmidt, M., and Birchmeier, W. (2004) Essential role of BCL9–2 in the switch between β-catenin’s adhesive and transcriptional functions. Genes Dev. 18, 2225–2230 CrossRef Medline

25. Hoffmans, R., and Basler, K. (2004) Identification and in vivo role of the Armadillo-Legless interaction. Development 131, 4393–4400 CrossRef Medline

26. Arend, R. C., Londoño-Joshi, A. I., Straughn, J. M., Jr., and Buchsbaum, D. J. (2013) The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol. Oncol. 131, 772–779 CrossRef Medline

27. Tsao, S. W., Mok, S. C., Fey, E. G., Fletcher, J. A., Wan, T. S., Chew, E. C., Muto, M. G., Knapp, R. C., and Berkowitz, R. S. (1995) Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp. Cell Res. 218, 499–507 CrossRef Medline

28. Xu, G., Craig, A. W., Greer, P., Miller, M., Anastasiadis, P. Z., Lilien, J., and Tonks, N. K. (2016) HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer. Genes Dev. 30, 1542–1557 CrossRef Medline

29. Lilien, J., and Balsamo, J. (2005) The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr. Opin. Cell Biol. 17, 459–465 CrossRef Medline

30. Zhang, S., Fan, G., Hsu, Y., Huang, Z., Liao, Y., Sun, X., and Zheng, D. (2011) Characterization of a new ARID family transcript for ‘PTP-ome’. J. Biol. Chem. 286, 233–241 CrossRef Medline

31. Liu, Q., Zheng, J., Sun, W., Huo, Y., Zhang, L., Yao, P., Wang, H., and Zhang, M. (2018) A proximity-tagging system to identify membrane protein–protein interactions. Nat. Methods 15, 715–722 CrossRef Medline

32. Pedrosa, E., Shah, A., Tenore, C., Capogna, M., Villa, C., Guo, X., Zheng, D., and Lachman, H. M. (2010) B-Catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network. J. Neurogenet. 24, 182–193 CrossRef Medline

33. Clevers, H., and Nusse, R. (2012) Wnt/β-catenin signaling and disease. Cell 149, 1192–1205 CrossRef Medline

34. Lammi, L., Arte, S., Somer, M., Jarvinen, H., Lahermo, P., Thesleff, I., Pirinen, S., and Nieminen, P. (2004) Mutations in AXIN2 cause familial adenomatous polyposis coli. Am. J. Hum. Genet. 74, 1043–1050 CrossRef Medline

35. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. (1997) Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787–1790 CrossRef Medline

36. Assié, G., Letouzé, E., Fassnacht, M., Jouniout, A., Luscap, W., Barreau, O., Omerei, H., Rodriguez, S., Perlemoine, K., René-Corail, F., Elarouci, N., Sbiera, S., Kroiss, M., Allolio, B., and Waldmann, J. et al. (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 CrossRef Medline

37. Su, P. H., Lin, Y. W., Huang, R. L., Liao, Y. P., Lee, H. Y., Yang, H. C., Chao, T. K., Chen, C. K., Chan, M. W., Chu, T. Y., Yu, M. H., and Lai, H. C. (2013) Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene 32, 15–26 CrossRef Medline

38. Rajan, P., and Elliott, D. J. (2015) Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer 15, 9 CrossRef Medline

39. Shen, S., Gui, T., and Ma, C. (2017) Identification of molecular biomarkers for pancreatic cancer with mRMR shortest path method. Oncotarget 8, 41432–41439 CrossRef Medline

40. Li, X., Liu, Z., Li, W., Sun, N., Xu, Y., Xie, Z., and Zhang, K. (2016) PTPRR regulates ERK dephosphorylation in depression mice model. J. Affect. Disord. 193, 233–241 CrossRef Medline

41. Wilsker, D., Probst, L., Wain, H. M., Maltais, L., Tucker, P. W., and Moran, E. (2005) Nomenclature of the ARID family of DNA-binding proteins. Genomics 86, 242–251 CrossRef Medline

42. Tidwell, J. A., Schmidt, C., Heaton, P., Wilson, V., and Tucker, P. W. (2011) Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. Mol. Immunol. 49, 260–272 CrossRef Medline

43. Kim, S., Zhang, Z., Upchurch, S., Isern, N., and Chen, Y. (2004) Structure and DNA-binding sites of the SWI1 AT-rich interaction domain (ARID) suggest determinants for sequence-specific DNA recognition. J. Biol. Chem. 279, 16670–16676 CrossRef Medline

44. Vo, M. J., Ho, P. Y., Zhang, Q. Y., Jian, C., Qiu, J. X., Kim, E. J., Bold, R. L., Gonzalez, F. I., Bi, H., and Yu, A. M. (2019) Bioengineered miRNA-1291 produrr therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Lett. 442, 82–90 CrossRef Medline

45. Nakahara, S., Fukushima, S., Yamashita, J., Kubo, Y., Tokuzumi, A., Miyashita, A., Harada, M., Nakamura, K., Jinnin, M., and Ihn, H. (2017) AT-rich interaction domain-containing protein 3B is a new tumour marker for melanoma. Acta Derm. Venereol. 97, 112–114 CrossRef Medline

46. Chien, C. S., Wang, M. L., Chu, P. Y., Chang, Y. L., Liu, W. H., Yu, C. C., Lan, T. Y., Huang, P. I., Lee, Y. Y., Chen, Y. W., Lo, W. L., and Chiou, S. H. (2015) Lin28B/Let-7 regulates expression of Oct4 and Sox2 and reprograms squamous cell carcinoma cells to a stem-like state. Cancer Res. 75, 2553–2565 CrossRef Medline

47. Cowden Dahl, K. D., Dahl, R., Kruichak, J. N., and Hudson, L. G. (2009) The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11, 1208–1215 CrossRef Medline

48. Bobbs, A., Gellerman, K., Hallas, W. M., Joseph, S., Yang, C., Kurkiewicz, J., and Cowden Dahl, K. D. (2015) ARID3B directly regulates ovarian cancer promoting genes. PLoS One 10, e0131961 CrossRef Medline

49. Roy, L., Sanyavedudas, S. J., Carrasco, M., Li, J., Joseph, S., Dahl, R., and Cowden Dahl, K. D. (2014) ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. Oncotarget 5, 8355–8366 CrossRef Medline

50. Lin, G., Aranda, V., Muthuswamy, S. K., and Tonks, N. K. (2011) Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the “PTP-ome”. Genes Dev. 25, 1412–1425 CrossRef Medline

51. Gao, Y., Xiao, Q., Ma, H., Li, L., Liu, J., Feng, Y., Fang, Z., Wu, J., Han, X., Zhang, J., Sun, Y., Wu, G., Paderia, R., Chen, H., Wong, K. et al. (2010) LKB1 inhibits lung cancer progression through lysis oxide and extracellular matrix remodeling. Proc. Natl. Acad. Sci. U.S.A. 107, 18892–18897 CrossRef Medline

52. Ren, S., Su, C., Wang, Z., Li, J., Fan, L., Li, B., Li, X., Zhao, C., Wu, C., Hou, L., He, Y., Gao, G., Chen, X., Ren, J., Li, A., Xu, G., Zhou, X., Zhou, C., and Schmid-Bindert, G. (2014) Epithelial phenotype as a predictive marker for
response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. *Int. J. Cancer* **135**, 2962–2971 CrossRef Medline

57. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Pérez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yilmaz, S., et al. (2019) The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450 CrossRef Medline

58. Nagy, Á., Lánczky, A., Menyhárt, O., and Gyrffy, B. (2018) Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Sci. Rep.* **8**, 9227 CrossRef Medline

59. Olson A., Sheth, N., Lee, J. S., Hannon, G., and Sachidanandam, R. (2006) RNAi Codex: a portal/database for short-hairpin RNA (shRNA) gene-silencing constructs. *Nucleic Acids Res.* **34**, D153–D157 CrossRef Medline

**PTPRR dephosphorylates and inactivates β-catenin**